I’m on the hunt for the best stocks on the market! I think I may have just found them

This Fool is on the lookout for the best the stock market has to offer. He reckons these two could be solid candidates.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Portrait of pensive bearded senior looking on screen of laptop sitting at table with coffee cup.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Investing in the stock market can be difficult. Nowadays, there’s so much information available to investors promoting things such as get-rich-quick schemes.

I’m blocking all that out. I invest in the market to build my wealth over time. I want top-quality businesses in my portfolio that I believe can perform strongly over a long stretch.

The stock market is vast, but I’ve put most of my energy into focusing on FTSE shares, which have gone on a tear this year. I like what I see with these two.

GSK

First is pharmaceutical giant GSK (LSE: GSK). The stock has taken full advantage of the market rally. It’s up 11.6% so far this year.

But with its share price sliding around 5% in the last week, I reckon now could be a time to swoop in and buy some shares. It trades on 15.1 times earnings. I see that as good value for a high-quality business.

GSK is on my list due to its defensive nature. Regardless of external issues such as a weak economy, people will always need access to medicine and treatments.

That’s not to say the stock is risk-free. For example, some market spectators have concerns about the firm’s drug pipeline. The company has underperformed compared to its peers recently. Furthermore, it’s facing further legal trouble surrounding heartburn drug Zantac, which sparked its fall recently.

But with it now having nearly 90 products in its R&D pipeline, it seems the firm is turning a corner. As such, analysts have its earnings growth rising from 3% this year to 10% and 11% in 2025 and 2026 respectively. Its 12-month price target is £19.51, which represents an 18.1% premium from its current price.

I like to target income. Therefore, its 3.6% yield, in line with the Footsie average, is also attractive.

Diageo

I also think one of the market’s best offerings right now is Diageo (LSE: DGE). Unlike GSK, its share price has faltered lately. It’s down 5.8% year to date. Diageo shares have lost 20.7% of their value in the last 12 months.

The spirit maker has struggled as consumers have cut back on splashing out on its premium brands in favour of cheaper alternatives given the current economic environment. Sales have been hit especially hard in the US, which is the company’s largest market.

But I still see an incredibly strong underlying business. The company owns high-quality names such as Guinness and Captain Morgan. In the years to come, I think demand for its products will steadily grow due to rising wealth in developing countries.

With its share price struggling, investors can now pick up Diageo shares trading on 19.2 times earnings. That’s above the Footsie average (11) but considerably lower than its historical average of around 24.

To go with that, the stock has a 3.1% yield. That may not seem enticing given some of the higher yields available on the Footsie. However, it has increased its payout for 37 years on the trot, which is an incredible record.

Charlie Keough has no position in any of the shares mentioned. The Motley Fool UK has recommended Diageo Plc and GSK. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Middle aged businesswoman using laptop while working from home
Investing For Beginners

I think the best days for Lloyds’ share price are over. Here’s why

Jon Smith explains why Lloyds' share price could come under increasing pressure over the coming year, with factors including a…

Read more »

A graph made of neon tubes in a room
Investing Articles

£5,000 invested in the FTSE 100 at the start of 2025 is now worth…

Looking to invest in the FTSE 100? Royston Wild believes buying individual shares could be the best way to target…

Read more »

Thoughtful man using his phone while riding on a train and looking through the window
Investing Articles

Can the BAE share price do it again in 2026?

The BAE share price has been in good form in 2025. But Paul Summers says a high valuation might be…

Read more »

Investing Articles

Can Rolls-Royce, Babcock, and BAE Systems shares do it all over again in 2026?

Harvey Jones examines whether BAE Systems and other defence-focused FTSE 100 stocks can continue to shoot the lights out in…

Read more »

Investing Articles

7 UK dividend shares yielding over 7% that could thrive if rates fall in 2026

Mark Hartley weighs up the investment benefits of interest rate changes and how they could boost the potential of seven…

Read more »

Investing Articles

These 3 things could make a Stocks and Shares ISA a no-brainer in 2026

The government and the FCA are doing their bit to try to steer investors towards a Stocks and Shares ISA…

Read more »

Businessman using pen drawing line for increasing arrow from 2024 to 2025
Investing Articles

Revealed! The 10 best-performing FTSE 100 shares in 2025

It's been a year of golden gains for the FTSE 100 index, spearheaded by these 10 powerhouse stocks. But can…

Read more »

Snowing on Jubilee Gardens in London at dusk
Investing Articles

Is it time to consider gobbling up these 3 FTSE 100 Christmas turkeys?

Our writer looks at the pros and cons of buying three of the FTSE 100’s (INDEXFTSE:UKX) worst performers over the…

Read more »